Eli Lilly and Company has announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…
Read More
OrsoBio’s LXR inverse agonist shows promise for hard-to-treat triglyceride disorders
OrsoBio, a specialized biotechnology firm dedicated to pioneering treatments for obesity and its associated metabolic disorders, is strategically charting a…
Read More
Sai Life Sciences plans to recruit 700+ professionals in FY27 as Indian CRDMO demand accelerates
Hyderabad-based Sai Life Sciences, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), has announced ambitious plans to hire more…
Read More
Novo Nordisk’s new weight loss treatment inferior to Lilly’s tirzepatide
Novo Nordisk’s latest investigational weight loss treatment, CagriSema, has failed to achieve its primary endpoint of demonstrating non-inferiority when compared…
Read More
Lilly is now the top pharma company by revenue as Mounjaro (+99%) and Zepbound (+175%) combine for $36.5B in FY2025
Eli Lilly and Company has officially ascended to the pinnacle of the global pharmaceutical industry, achieving the coveted position of…
Read More
Novo Nordisk’s triple agonist delivers up to 19.7% average weight loss in Phase 2 trial
Novo Nordisk’s investigational triple agonist, UBT251, has demonstrated a mean weight loss of 19.7% after 24 weeks in a Phase…
Read More
Moving beyond the binary: how the convergence of small and large molecules is reshaping pharmaceutical R&D
Pharmaceutical research and development is experiencing a profound transformation, marked by an unprecedented convergence of technological advancements, vast data streams,…
Read More
Pharma 2035 Playbook: Speed, focus and conviction in an uncertain world
The pharmaceutical industry, perpetually at the vanguard of scientific innovation, finds itself navigating an increasingly turbulent global landscape. Characterized by…
Read More
DenovAI’s physics-based bet on one-shot drug design
Rethinking the Drug Discovery Paradigm For decades, the pharmaceutical industry has operated on a well-established, albeit arduous, pipeline: identify "hit"…
Read More
Cellares Raises $257M Series D to Automate Cell Therapy Manufacturing
The burgeoning field of cell and gene therapy, heralded as a revolutionary frontier in medicine, is currently grappling with a…
Read MoreYOU MAY HAVE MISSED
